Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma

Video

In Partnership With:

David J. Straus, MD, internist and hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) as a treatment for patients with Hodgkin lymphoma.

David J. Straus, MD, internist and hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) as a treatment for patients with Hodgkin lymphoma.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Núria Agustí Garcia, MD
Erin Frances Cobain, MD
Kian-Huat Lim, MD, PhD
Joaquim Bellmunt, MD, PhD
Related Content
Rebecca Klisovic, MD, of University Hospitals Seidman Cancer Center

Which JAK Inhibitor in Myelofibrosis: Deciding Factors in Treatment Selection

May 3rd 2024
Article
Ryan Merkow, MD, MS, associate professor, surgery, director, Surgical Cancer Quality, associate director, Health Services Research, Department of Surgery, director, Hepatic Artery Infusion Pump Program, University of Chicago Medicine Comprehensive Cancer Center and Cancer Service Line; Louise Catherine Connell, MB BCh BAO, BMedSc, assistant attending physician, Memorial Sloan Kettering Cancer Center

Merkow and Connell Highlight Considerations for HAI Pump Use in CRC

May 2nd 2024
Podcast
Jonathan E. Rosenberg, MD

ADCs and Immunotherapy Broaden the Bladder Cancer Treatment Paradigm

May 2nd 2024
Article
Saad Z. Usmani, MD, MBA, FACP, FASCO, hematologist-oncologist, chief, Myeloma Service, Memorial Sloan Kettering Cancer Center

FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy

April 22nd 2024
Podcast
Marjorie Green, MD

Frontline Pembrolizumab Plus Trastuzumab/Chemo Meets OS End Point in HER2+ Gastric/GEJ Cancer

May 1st 2024
Article
FDA

NK Cell Therapy IGNK001 Receives FDA Orphan Drug Designation for AML

April 30th 2024
Article